Navigation Links
PDL BioPharma Announces Conversion Rate Adjustments for 2.00% Convertible Senior Notes Due February 15, 2012 and 2.875% Convertible Senior Notes Due February 15, 2015
Date:3/8/2011

INCLINE VILLAGE, Nev., March 8, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced an adjustment to the conversion rate for its 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) and its 2.875% Convertible Senior Notes due February 15, 2015 (the 2015 Notes) effective March 7, 2011, in connection with the regular dividend to be paid on March 15, 2011, to all stockholders who own shares of PDL on March 8, 2011, the record date.

The conversion rate for the 2012 Notes and the 2015 Notes, as adjusted, is 144.474 shares of common stock per $1,000 principal amount or $6.92 per share. The conversion rate for the 2012 Notes and the 2015 Notes was previously 140.571 shares of common stock per $1,000 principal amount of the 2012 Notes and the 2015 Notes. In connection with a cash dividend, the conversion rate is increased by multiplying the previous conversion rate by a fraction, the numerator of which is the average closing price of PDL's common stock for the five consecutive trading days immediately preceding the ex-dividend date of March 4, 2011, for the cash dividend, and the denominator of which is the difference of such average closing price less the dividend amount.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements

The foregoing statements regarding PDL's intentions with respect to the quarterly dividend payment described above are forward-looking statements under the Private Securities Litigation Reform Act of 1995, and actual results could vary materially from the statements made. PDL's ability to pay the dividend described above is subject to various risks, many of which are outside its control, including prevailing conditions in the capital markets, the continued strength of its royalty assets and other risks and uncertainties as detailed from time to time in the reports filed by PDL with the Securities and Exchange Commission.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
2. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
3. Genesis Biopharma Names Marvin S. Hausman M.D. as Chief Science Officer
4. PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million
5. PDL BioPharma Announces Fourth Quarter and Full Year 2010 Financial Results
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. PDL BioPharma Announces European Patent Office Determination of Validity of PDLs European Patent is Final
8. PDL BioPharma Announces Regular Quarterly Dividend Policy
9. PDL BioPharma to Present at Upcoming Conferences
10. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
11. Success Factors and Failure Points in Biopharmaceutical Product Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)...  Fortuna Fix Inc. (" Fortuna "), a private, ... eliminate the need for embryonic and fetal stem cells by ... Fortuna announced today the launch of ... , MD, PhD; Father Kevin FitzGerald , S.J., PhD; ... James Giordano , PhD. "We are excited ...
(Date:5/4/2017)... DIEGO , May 4, 2017  The American ... and Scientific Meeting— OBP Medical , a leading global ... the launch of a new extra-small size and first-in-market ... ER-SPEC vaginal specula. Already available in small, medium, ... makes OBP Medical,s line of single-use lighted specula the ...
(Date:5/4/2017)... BOTHELL, Wash. , May 4, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... media ("BioLife" or the "Company"), today announced that ... released after market close on Thursday, May 11, 2017, ... and live webcast at 1:30 p.m. PT that afternoon. ...
Breaking Medicine Technology:
(Date:5/28/2017)... Winter Haven, FL (PRWEB) , ... May 28, ... ... Physician Partners of America (PPOA), is proud to announce that Sheldon K. Cho, ... on comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques ...
(Date:5/27/2017)... ... ... dentist? You should go twice per year for checkups, but if you want to keep ... some dental tips to help out: , 1. Brushing Teeth - Brush your teeth twice ... locker at school for a quick brushing after lunch. Use a small brush head with ...
(Date:5/27/2017)... Santa Rosa, CA (PRWEB) , ... May 27, 2017 , ... ... show cause for concern, but a new study from the Osteoarthritis Initiative ... vulnerable to developing knee osteoarthritis. Knowing this in advance may give doctors the opportunity ...
(Date:5/26/2017)... Massachsetts (PRWEB) , ... May 26, 2017 , ... ... will gather at Boston CEO 2017 on May 30th and 31st at The ... networking forum for leading executives in the life sciences, offering exclusive access to ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware ... for diagnostic device operations. With this platform, initializing devices and importing studies are ...
Breaking Medicine News(10 mins):